Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series

Abstract Background and purpose Idiopathic multifocal choroiditis (MFC) is part of the group of choriocapillaritis entities. The clinical definition of the disease has evolved with time. The aim of this article was to undertake a review on MFC, on its present-day appraisal and nomenclature and we al...

Full description

Bibliographic Details
Main Authors: Ioannis Papasavvas, Piergiorgio Neri, Alessandro Mantovani, Carl P. Herbort
Format: Article
Language:English
Published: SpringerOpen 2022-01-01
Series:Journal of Ophthalmic Inflammation and Infection
Subjects:
Online Access:https://doi.org/10.1186/s12348-021-00278-8
_version_ 1828138510839709696
author Ioannis Papasavvas
Piergiorgio Neri
Alessandro Mantovani
Carl P. Herbort
author_facet Ioannis Papasavvas
Piergiorgio Neri
Alessandro Mantovani
Carl P. Herbort
author_sort Ioannis Papasavvas
collection DOAJ
description Abstract Background and purpose Idiopathic multifocal choroiditis (MFC) is part of the group of choriocapillaritis entities. The clinical definition of the disease has evolved with time. The aim of this article was to undertake a review on MFC, on its present-day appraisal and nomenclature and we also report a series of patients with emphasis on the clinical presentation and the importance of vigorous immunosuppressive management. Methods A review of the literature and a retrospective case series study which was performed in the Centre for Ophthalmic Specialised care (COS), Lausanne, Switzerland. Patients diagnosed from 1994 to 2020 with idiopathic multifocal choroiditis (MFC) treated with multiple immunosuppressants were included. Exclusion criteria were insufficient follow up and cases not treated with vigorous immunosuppressive therapy. Imaging analysis included spectral domain optical coherence tomography (SD-OCT) / enhanced depth imaging OCT (EDI-OCT), OCT angiography (OCT-A). Fluorescein and Indocyanine angiography (FA, ICGA) before and after the instauration of treatment. Best corrected visual acuity (BCVA), intraocular pressure (IOP), routine ocular examination, laser flare photometry (LFP) were performed at presentation and follow-up. Immunosuppression comprised at minimum two among the following agents: prednisone, cyclosporine, azathioprine, mycophenolic acid or infliximab. Mean duration of therapy was calculated. Results 26 (52 eyes) of 2102 new patients (1.24%) were diagnosed with MFC. 25 (96%) patients were female and 1 (4%) was male. 43/52 (82%) eyes were myopic with a mean dioptre of − 5.87 ± 2.94, six (12%) eyes were hypermetropic with mean dioptres 2.0 ± 2.68 and three (6%) were emmetropic. 14/52 (27%) eyes had at least 1 anti-VEGF injection because of choroidal neovascularisation (CNVs), 1 eye had a phototherapy laser and 37/52 (71%) had no complication of CNVs during the follow-up. 5/26 (19%) fulfilled the inclusion criteria for our study. Mean age was 26.4 ± 9.3 years. Snellen best corrected visual acuity (BCVA) at presentation was 0.955+/-0.26. Mean follow up was 84+/-55 months. LFP at presentation was 6.34 ± 2.94 ph/ms. None of four patients with prolonged treatment and prolonged follow-up showed disease activity. One patient still under therapy after 4 months’ follow-up still showed an active neovascular membrane. Conclusion Treatment with multiple immunosuppressive agents was shown to stop the progression of the disease.
first_indexed 2024-04-11T18:37:00Z
format Article
id doaj.art-e8797d2cc5ad44818c7c4c50bebb0f7f
institution Directory Open Access Journal
issn 1869-5760
language English
last_indexed 2024-04-11T18:37:00Z
publishDate 2022-01-01
publisher SpringerOpen
record_format Article
series Journal of Ophthalmic Inflammation and Infection
spelling doaj.art-e8797d2cc5ad44818c7c4c50bebb0f7f2022-12-22T04:09:13ZengSpringerOpenJournal of Ophthalmic Inflammation and Infection1869-57602022-01-0112111810.1186/s12348-021-00278-8Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case seriesIoannis Papasavvas0Piergiorgio Neri1Alessandro Mantovani2Carl P. Herbort3Retinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialized Care (COS)The Eye Institute, Cleveland Clinic Abu DhabiDepartment of Ophthalmology, Valduce HospitalRetinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialized Care (COS)Abstract Background and purpose Idiopathic multifocal choroiditis (MFC) is part of the group of choriocapillaritis entities. The clinical definition of the disease has evolved with time. The aim of this article was to undertake a review on MFC, on its present-day appraisal and nomenclature and we also report a series of patients with emphasis on the clinical presentation and the importance of vigorous immunosuppressive management. Methods A review of the literature and a retrospective case series study which was performed in the Centre for Ophthalmic Specialised care (COS), Lausanne, Switzerland. Patients diagnosed from 1994 to 2020 with idiopathic multifocal choroiditis (MFC) treated with multiple immunosuppressants were included. Exclusion criteria were insufficient follow up and cases not treated with vigorous immunosuppressive therapy. Imaging analysis included spectral domain optical coherence tomography (SD-OCT) / enhanced depth imaging OCT (EDI-OCT), OCT angiography (OCT-A). Fluorescein and Indocyanine angiography (FA, ICGA) before and after the instauration of treatment. Best corrected visual acuity (BCVA), intraocular pressure (IOP), routine ocular examination, laser flare photometry (LFP) were performed at presentation and follow-up. Immunosuppression comprised at minimum two among the following agents: prednisone, cyclosporine, azathioprine, mycophenolic acid or infliximab. Mean duration of therapy was calculated. Results 26 (52 eyes) of 2102 new patients (1.24%) were diagnosed with MFC. 25 (96%) patients were female and 1 (4%) was male. 43/52 (82%) eyes were myopic with a mean dioptre of − 5.87 ± 2.94, six (12%) eyes were hypermetropic with mean dioptres 2.0 ± 2.68 and three (6%) were emmetropic. 14/52 (27%) eyes had at least 1 anti-VEGF injection because of choroidal neovascularisation (CNVs), 1 eye had a phototherapy laser and 37/52 (71%) had no complication of CNVs during the follow-up. 5/26 (19%) fulfilled the inclusion criteria for our study. Mean age was 26.4 ± 9.3 years. Snellen best corrected visual acuity (BCVA) at presentation was 0.955+/-0.26. Mean follow up was 84+/-55 months. LFP at presentation was 6.34 ± 2.94 ph/ms. None of four patients with prolonged treatment and prolonged follow-up showed disease activity. One patient still under therapy after 4 months’ follow-up still showed an active neovascular membrane. Conclusion Treatment with multiple immunosuppressive agents was shown to stop the progression of the disease.https://doi.org/10.1186/s12348-021-00278-8Multifocal choroiditisFAICGAPrimary inflammatory choriocapillaropathies
spellingShingle Ioannis Papasavvas
Piergiorgio Neri
Alessandro Mantovani
Carl P. Herbort
Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series
Journal of Ophthalmic Inflammation and Infection
Multifocal choroiditis
FA
ICGA
Primary inflammatory choriocapillaropathies
title Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series
title_full Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series
title_fullStr Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series
title_full_unstemmed Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series
title_short Idiopathic multifocal choroiditis (MFC): aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease. An offbeat review and a case series
title_sort idiopathic multifocal choroiditis mfc aggressive and prolonged therapy with multiple immunosuppressive agents is needed to halt the progression of active disease an offbeat review and a case series
topic Multifocal choroiditis
FA
ICGA
Primary inflammatory choriocapillaropathies
url https://doi.org/10.1186/s12348-021-00278-8
work_keys_str_mv AT ioannispapasavvas idiopathicmultifocalchoroiditismfcaggressiveandprolongedtherapywithmultipleimmunosuppressiveagentsisneededtohalttheprogressionofactivediseaseanoffbeatreviewandacaseseries
AT piergiorgioneri idiopathicmultifocalchoroiditismfcaggressiveandprolongedtherapywithmultipleimmunosuppressiveagentsisneededtohalttheprogressionofactivediseaseanoffbeatreviewandacaseseries
AT alessandromantovani idiopathicmultifocalchoroiditismfcaggressiveandprolongedtherapywithmultipleimmunosuppressiveagentsisneededtohalttheprogressionofactivediseaseanoffbeatreviewandacaseseries
AT carlpherbort idiopathicmultifocalchoroiditismfcaggressiveandprolongedtherapywithmultipleimmunosuppressiveagentsisneededtohalttheprogressionofactivediseaseanoffbeatreviewandacaseseries